Dopamine, Locus of Control, and the Exploration-Exploitation Tradeoff

Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenc...

Full description

Saved in:
Bibliographic Details
Published inNeuropsychopharmacology (New York, N.Y.) Vol. 40; no. 2; pp. 454 - 462
Main Authors Kayser, Andrew S, Mitchell, Jennifer M, Weinstein, Dawn, Frank, Michael J
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.01.2015
Subjects
Online AccessGet full text
ISSN0893-133X
1740-634X
1740-634X
DOI10.1038/npp.2014.193

Cover

Abstract Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenced by a functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT) gene, whose protein product degrades synaptically released dopamine. However, these and other genotype-phenotype associations have rarely been causally tested. To directly test this association and to evaluate additional behavioral characteristics, including perceived locus of control (LOC), here we used the COMT inhibitor tolcapone in a randomized, double-blind, counterbalanced, within-subject study of 66 subjects genotyped for the Val158Met allele to assess the hypothesis that reducing COMT enzymatic activity interacts with genotype to increase uncertainty-driven exploration. In keeping with our initial hypothesis, tolcapone led to an increase in exploratory, but not exploitative, behavior in Met/Met rather than Val/Val subjects. Independent of genotype, those subjects with a more external LOC also showed increases in uncertainty-driven exploration on tolcapone relative to placebo. However, we did not replicate our previous finding that Met/Met subjects show greater exploration at baseline. Together these findings support a model in which exploration is hypothesized to have a dopaminergic basis. Moreover, in keeping with findings in other behavioral and cognitive domains, the response to an increase in presumptively frontal dopamine is dependent upon baseline dopamine tone.
AbstractList Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenced by a functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT) gene, whose protein product degrades synaptically released dopamine. However, these and other genotype-phenotype associations have rarely been causally tested. To directly test this association and to evaluate additional behavioral characteristics, including perceived locus of control (LOC), here we used the COMT inhibitor tolcapone in a randomized, double-blind, counterbalanced, within-subject study of 66 subjects genotyped for the Val158Met allele to assess the hypothesis that reducing COMT enzymatic activity interacts with genotype to increase uncertainty-driven exploration. In keeping with our initial hypothesis, tolcapone led to an increase in exploratory, but not exploitative, behavior in Met/Met rather than Val/Val subjects. Independent of genotype, those subjects with a more external LOC also showed increases in uncertainty-driven exploration on tolcapone relative to placebo. However, we did not replicate our previous finding that Met/Met subjects show greater exploration at baseline. Together these findings support a model in which exploration is hypothesized to have a dopaminergic basis. Moreover, in keeping with findings in other behavioral and cognitive domains, the response to an increase in presumptively frontal dopamine is dependent upon baseline dopamine tone.
Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenced by a functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT) gene, whose protein product degrades synaptically released dopamine. However, these and other genotype-phenotype associations have rarely been causally tested. To directly test this association and to evaluate additional behavioral characteristics, including perceived locus of control (LOC), here we used the COMT inhibitor tolcapone in a randomized, double-blind, counterbalanced, within-subject study of 66 subjects genotyped for the Val158Met allele to assess the hypothesis that reducing COMT enzymatic activity interacts with genotype to increase uncertainty-driven exploration. In keeping with our initial hypothesis, tolcapone led to an increase in exploratory, but not exploitative, behavior in Met/Met rather than Val/Val subjects. Independent of genotype, those subjects with a more external LOC also showed increases in uncertainty-driven exploration on tolcapone relative to placebo. However, we did not replicate our previous finding that Met/Met subjects show greater exploration at baseline. Together these findings support a model in which exploration is hypothesized to have a dopaminergic basis. Moreover, in keeping with findings in other behavioral and cognitive domains, the response to an increase in presumptively frontal dopamine is dependent upon baseline dopamine tone.Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision. Recent computational studies of this exploration-exploitation tradeoff have found that variability in exploration across individuals is influenced by a functional polymorphism (Val158Met) in the catechol-O-methyltransferase (COMT) gene, whose protein product degrades synaptically released dopamine. However, these and other genotype-phenotype associations have rarely been causally tested. To directly test this association and to evaluate additional behavioral characteristics, including perceived locus of control (LOC), here we used the COMT inhibitor tolcapone in a randomized, double-blind, counterbalanced, within-subject study of 66 subjects genotyped for the Val158Met allele to assess the hypothesis that reducing COMT enzymatic activity interacts with genotype to increase uncertainty-driven exploration. In keeping with our initial hypothesis, tolcapone led to an increase in exploratory, but not exploitative, behavior in Met/Met rather than Val/Val subjects. Independent of genotype, those subjects with a more external LOC also showed increases in uncertainty-driven exploration on tolcapone relative to placebo. However, we did not replicate our previous finding that Met/Met subjects show greater exploration at baseline. Together these findings support a model in which exploration is hypothesized to have a dopaminergic basis. Moreover, in keeping with findings in other behavioral and cognitive domains, the response to an increase in presumptively frontal dopamine is dependent upon baseline dopamine tone.
Author Frank, Michael J
Mitchell, Jennifer M
Kayser, Andrew S
Weinstein, Dawn
Author_xml – sequence: 1
  givenname: Andrew S
  surname: Kayser
  fullname: Kayser, Andrew S
– sequence: 2
  givenname: Jennifer M
  surname: Mitchell
  fullname: Mitchell, Jennifer M
– sequence: 3
  givenname: Dawn
  surname: Weinstein
  fullname: Weinstein, Dawn
– sequence: 4
  givenname: Michael J
  surname: Frank
  fullname: Frank, Michael J
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25074639$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1P3DAQxS1EVRbojXMVqRcOm60n_sylElqWFmmlXkDiZjmOXYKydrATRP_7emGpCuLQ03jk3zy9mXeI9n3wFqETwAvARH71w7CoMNAF1GQPzUBQXHJCb_bRDMualEDIzQE6TOkOY2CCy4_ooGJYUE7qGVqdh0FvOm_nxTqYKRXBFcvgxxj6eaF9W4y3tlg9Dn2IeuyCL5_e3fjUFFdRtzY4d4w-ON0n-2lXj9D1xepq-aNc__x-uTxbl4YKOZbEasMqkMY5YI22TcUbgR2I1hoQzDUgWwaNqXmt20pz3GKBeWM4YUAYbcgR-vasO0zNxrbGZqO6V0PsNjr-VkF36vWP727Vr_CgKKWk5jgLnO4EYrifbBrVpkvG9r32NkxJAee0wpII-h8oEYxVkm_RL2_QuzBFny-xpRgmQoLI1Od_zf91_RJGBqpnwMSQUrROmd2h8y5drwCrbeIqJ662iauceB6avxl60X0X_wMonqyz
CODEN NEROEW
CitedBy_id crossref_primary_10_3389_fnins_2016_00106
crossref_primary_10_3389_fnins_2019_00065
crossref_primary_10_1111_gbb_12228
crossref_primary_10_1371_journal_pone_0176034
crossref_primary_10_1038_s41398_021_01512_6
crossref_primary_10_1038_s41386_021_01100_8
crossref_primary_10_17759_jmfp_2020090208
crossref_primary_10_1017_S1092852924000130
crossref_primary_10_1162_jocn_a_01641
crossref_primary_10_1007_s00213_020_05599_5
crossref_primary_10_1016_j_neunet_2020_03_005
crossref_primary_10_7554_eLife_59907
crossref_primary_10_1523_JNEUROSCI_1607_20_2021
crossref_primary_10_1016_j_psyneuen_2017_09_010
crossref_primary_10_3389_fnint_2018_00006
crossref_primary_10_1016_j_tics_2015_08_013
crossref_primary_10_7554_eLife_51260
crossref_primary_10_1016_j_neubiorev_2020_04_006
crossref_primary_10_1016_j_neuron_2019_07_021
crossref_primary_10_1371_journal_pcbi_1006989
crossref_primary_10_1007_s00213_019_05299_9
crossref_primary_10_1111_psyp_14571
crossref_primary_10_1002_wcs_1420
crossref_primary_10_1016_j_cobeha_2021_04_003
crossref_primary_10_1016_j_neuroscience_2021_05_010
crossref_primary_10_1080_17405629_2020_1816166
crossref_primary_10_1038_s41380_021_01363_z
crossref_primary_10_1038_s41386_022_01517_9
crossref_primary_10_1016_j_brainres_2019_05_039
crossref_primary_10_1111_ejn_16426
crossref_primary_10_1038_ncomms10785
crossref_primary_10_1162_jocn_a_00896
crossref_primary_10_1523_ENEURO_0461_19_2020
crossref_primary_10_1007_s00213_018_4971_z
crossref_primary_10_1016_j_nicl_2016_12_022
crossref_primary_10_1111_psyp_14381
crossref_primary_10_1016_j_neuroimage_2018_10_075
crossref_primary_10_1007_s40429_019_00240_8
crossref_primary_10_1016_j_jbi_2021_103913
crossref_primary_10_1016_j_neuron_2015_12_029
crossref_primary_10_1038_npp_2017_108
crossref_primary_10_1016_j_tics_2015_11_007
crossref_primary_10_3758_s13415_021_00917_6
crossref_primary_10_1016_j_neuron_2024_04_008
crossref_primary_10_1016_j_ijpsycho_2019_09_016
crossref_primary_10_1016_j_pneurobio_2022_102252
crossref_primary_10_7554_eLife_74149
crossref_primary_10_1371_journal_pone_0282727
crossref_primary_10_1038_npp_2015_208
Cites_doi 10.1038/sj.npp.1301227
10.1016/j.neuron.2011.12.025
10.1016/j.neunet.2007.04.026
10.1016/j.biopsych.2011.03.028
10.1016/j.paid.2003.11.001
10.1523/JNEUROSCI.1180-12.2012
10.1073/pnas.95.17.9991
10.1016/j.bandc.2006.04.004
10.1038/nature04766
10.1038/nn.2723
10.1111/j.1460-9568.2009.06647.x
10.1371/journal.pone.0087109
10.1097/01.alc.0000191755.63639.4a
10.1097/00001756-199711100-00032
10.1037/a0037015
10.1007/s00213-012-2653-9
10.1093/cercor/bhr332
10.1016/j.biopsych.2010.10.015
10.1523/JNEUROSCI.3116-08.2008
10.1038/npp.2010.96
10.1002/syn.10034
10.1037/h0092976
10.1086/425589
10.1038/nn.2342
10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1
10.1111/j.1469-8749.2008.02026.x
10.1038/nrn1343
ContentType Journal Article
Copyright Copyright Nature Publishing Group Jan 2015
Copyright © 2015 American College of Neuropsychopharmacology 2015 American College of Neuropsychopharmacology
Copyright_xml – notice: Copyright Nature Publishing Group Jan 2015
– notice: Copyright © 2015 American College of Neuropsychopharmacology 2015 American College of Neuropsychopharmacology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TK
7X7
7XB
88E
88G
8AO
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2M
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
5PM
DOI 10.1038/npp.2014.193
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
ProQuest Health & Medical Collection
Medical Database
Psychology Database (ProQuest)
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Biological Science Database
ProQuest SciTech Collection
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest One Psychology
MEDLINE - Academic
MEDLINE
Neurosciences Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Dopamine and exploration
EISSN 1740-634X
EndPage 462
ExternalDocumentID PMC4443960
3522567981
25074639
10_1038_npp_2014_193
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States--US
San Francisco California
GeographicLocations_xml – name: San Francisco California
– name: United States--US
GroupedDBID ---
-DZ
-Q-
0R~
29N
2WC
36B
39C
4.4
406
5RE
70F
7X7
88E
8AO
8FI
8FJ
8R4
8R5
AANZL
AASML
AAYXX
AAYZH
ABAKF
ABBRH
ABDBE
ABFSG
ABIVO
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACKTT
ACMFV
ACMJI
ACPRK
ACRQY
ACSTC
ACZOJ
ADBBV
ADFRT
AEFQL
AEJRE
AEMSY
AENEX
AESKC
AEVLU
AEXYK
AEZWR
AFBBN
AFDZB
AFHIU
AFKRA
AFRAH
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AHWEU
AIGIU
AILAN
AIXLP
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
AOIJS
ASPBG
ATHPR
AVWKF
AYFIA
AZFZN
AZQEC
BAWUL
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
CS3
DIK
DNIVK
DPUIP
DWQXO
E3Z
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMOBN
F5P
FDB
FDQFY
FERAY
FIZPM
FSGXE
FYUFA
GNUQQ
GX1
HCIFZ
HMCUK
HYE
HZ~
IWAJR
JSO
JZLTJ
KQ8
M1P
M2M
M7P
MK0
NQJWS
O9-
OK1
P2P
P6G
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
PSYQQ
Q2X
RNT
RNTTT
ROL
RPM
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TR2
UKHRP
W2D
ZGI
--K
1B1
53G
5VS
AACDK
AAEDT
AALRI
AAQFI
AAQXK
AATNV
AAXUO
ABMAC
ABWVN
ACIUM
ACRPL
ADMUD
ADNMO
CAG
CGR
COF
CUY
CVF
ECM
EIF
FEDTE
FGOYB
FIGPU
HVGLF
IHE
LGEZI
LOTEE
M41
NADUK
NPM
NQ-
NXXTH
R2-
RIG
RNS
RPZ
SEW
SSZ
ZKB
3V.
7TK
7XB
8FE
8FH
8FK
ABRTQ
K9.
LK8
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c478t-3eac5218cff15baeb26b70f17dec175fb18d51bc969ad2a60d0706bc6351354b3
IEDL.DBID BENPR
ISSN 0893-133X
1740-634X
IngestDate Thu Aug 21 18:33:02 EDT 2025
Fri Sep 05 09:08:42 EDT 2025
Fri Sep 05 04:25:16 EDT 2025
Fri Jul 25 09:02:19 EDT 2025
Thu Apr 03 07:09:10 EDT 2025
Tue Jul 01 01:05:28 EDT 2025
Thu Apr 24 22:58:03 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c478t-3eac5218cff15baeb26b70f17dec175fb18d51bc969ad2a60d0706bc6351354b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://www.nature.com/articles/npp2014193.pdf
PMID 25074639
PQID 1635037817
PQPubID 33935
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4443960
proquest_miscellaneous_1664208374
proquest_miscellaneous_1637552864
proquest_journals_1635037817
pubmed_primary_25074639
crossref_citationtrail_10_1038_npp_2014_193
crossref_primary_10_1038_npp_2014_193
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2015-01-01
PublicationDateYYYYMMDD 2015-01-01
PublicationDate_xml – month: 01
  year: 2015
  text: 2015-01-01
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: New York
PublicationTitle Neuropsychopharmacology (New York, N.Y.)
PublicationTitleAlternate Neuropsychopharmacology
PublicationYear 2015
Publisher Nature Publishing Group
Publisher_xml – name: Nature Publishing Group
References J Chen (BFnpp2014193_CR5) 2004; 75
TV Maia (BFnpp2014193_CR18) 2011; 14
AS Kayser (BFnpp2014193_CR16) 2012; 32
N Ramnani (BFnpp2014193_CR22) 2004; 5
JB Rotter (BFnpp2014193_CR23) 1966; 80
JA Gogos (BFnpp2014193_CR14) 1998; 95
MJ Frank (BFnpp2014193_CR13) 2011; 36
JM Mitchell (BFnpp2014193_CR19) 2005; 29
CD Spielberger (BFnpp2014193_CR25) 1983
DY Kimberg (BFnpp2014193_CR17) 1997; 8
R Cools (BFnpp2014193_CR7) 2011; 69
JH Patton (BFnpp2014193_CR21) 1995; 51
MJ Frank (BFnpp2014193_CR12) 2009; 12
D Badre (BFnpp2014193_CR2) 2012; 73
R Ceravolo (BFnpp2014193_CR4) 2002; 43
B De Brabander (BFnpp2014193_CR9) 2004; 37
C Stelzel (BFnpp2014193_CR26) 2009; 29
CH Declerck (BFnpp2014193_CR10) 2006; 62
AG Collins (BFnpp2014193_CR6) 2014; 121
JA Apud (BFnpp2014193_CR1) 2007; 32
I Dumontheil (BFnpp2014193_CR11) 2008; 50
CT Smith (BFnpp2014193_CR24) 2012; 222
GP Strauss (BFnpp2014193_CR27) 2011; 69
ND Daw (BFnpp2014193_CR8) 2006; 441
K Kalidindi (BFnpp2014193_CR15) 2007; 20
J Vytlacil (BFnpp2014193_CR28) 2014; 9
JF Cavanagh (BFnpp2014193_CR3) 2012; 22
AA Moustafa (BFnpp2014193_CR20) 2008; 28
17063156 - Neuropsychopharmacology. 2007 May;32(5):1011-20
9707588 - Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9991-6
11793426 - Synapse. 2002 Mar 1;43(3):201-7
20631684 - Neuropsychopharmacology. 2011 Jan;36(1):133-52
16778890 - Nature. 2006 Jun 15;441(7095):876-9
9427330 - Neuroreport. 1997 Nov 10;8(16):3581-5
16806623 - Brain Cogn. 2006 Nov;62(2):143-76
19020023 - J Neurosci. 2008 Nov 19;28(47):12294-304
16385186 - Alcohol Clin Exp Res. 2005 Dec;29(12):2158-69
22349272 - Psychopharmacology (Berl). 2012 Aug;222(4):609-17
19291230 - Eur J Neurosci. 2009 Mar;29(5):1056-63
5340840 - Psychol Monogr. 1966;80(1):1-28
17574813 - Neural Netw. 2007 Aug;20(6):676-89
21168124 - Biol Psychiatry. 2011 Mar 1;69(5):424-31
14976518 - Nat Rev Neurosci. 2004 Mar;5(3):184-94
22120491 - Cereb Cortex. 2012 Nov;22(11):2575-86
8778124 - J Clin Psychol. 1995 Nov;51(6):768-74
21531388 - Biol Psychiatry. 2011 Jun 15;69(12):e113-25
24498023 - PLoS One. 2014;9(1):e87109
15457404 - Am J Hum Genet. 2004 Nov;75(5):807-21
19620978 - Nat Neurosci. 2009 Aug;12(8):1062-8
22325209 - Neuron. 2012 Feb 9;73(3):595-607
21270784 - Nat Neurosci. 2011 Feb;14(2):154-62
25090423 - Psychol Rev. 2014 Jul;121(3):337-66
22764248 - J Neurosci. 2012 Jul 4;32(27):9402-9
18190537 - Dev Med Child Neurol. 2008 Mar;50(3):168-81
References_xml – volume: 32
  start-page: 1011
  year: 2007
  ident: BFnpp2014193_CR1
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1301227
– volume: 73
  start-page: 595
  year: 2012
  ident: BFnpp2014193_CR2
  publication-title: Neuron
  doi: 10.1016/j.neuron.2011.12.025
– volume: 20
  start-page: 676
  year: 2007
  ident: BFnpp2014193_CR15
  publication-title: Neural Netw
  doi: 10.1016/j.neunet.2007.04.026
– volume: 69
  start-page: e113
  year: 2011
  ident: BFnpp2014193_CR7
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2011.03.028
– volume: 37
  start-page: 735
  year: 2004
  ident: BFnpp2014193_CR9
  publication-title: Personality and Individual Differences
  doi: 10.1016/j.paid.2003.11.001
– volume-title: Manual for the state-trait anxiety inventory
  year: 1983
  ident: BFnpp2014193_CR25
– volume: 32
  start-page: 9402
  year: 2012
  ident: BFnpp2014193_CR16
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.1180-12.2012
– volume: 95
  start-page: 9991
  year: 1998
  ident: BFnpp2014193_CR14
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.95.17.9991
– volume: 62
  start-page: 143
  year: 2006
  ident: BFnpp2014193_CR10
  publication-title: Brain Cogn
  doi: 10.1016/j.bandc.2006.04.004
– volume: 441
  start-page: 876
  year: 2006
  ident: BFnpp2014193_CR8
  publication-title: Nature
  doi: 10.1038/nature04766
– volume: 14
  start-page: 154
  year: 2011
  ident: BFnpp2014193_CR18
  publication-title: Nat Neurosci
  doi: 10.1038/nn.2723
– volume: 29
  start-page: 1056
  year: 2009
  ident: BFnpp2014193_CR26
  publication-title: Eur J Neurosci
  doi: 10.1111/j.1460-9568.2009.06647.x
– volume: 9
  start-page: e87109
  year: 2014
  ident: BFnpp2014193_CR28
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0087109
– volume: 29
  start-page: 2158
  year: 2005
  ident: BFnpp2014193_CR19
  publication-title: Alcohol Clin Exp Res
  doi: 10.1097/01.alc.0000191755.63639.4a
– volume: 8
  start-page: 3581
  year: 1997
  ident: BFnpp2014193_CR17
  publication-title: Neuroreport
  doi: 10.1097/00001756-199711100-00032
– volume: 121
  start-page: 337
  year: 2014
  ident: BFnpp2014193_CR6
  publication-title: Psychol Rev
  doi: 10.1037/a0037015
– volume: 222
  start-page: 609
  year: 2012
  ident: BFnpp2014193_CR24
  publication-title: Psychopharmacology (Berl)
  doi: 10.1007/s00213-012-2653-9
– volume: 22
  start-page: 2575
  year: 2012
  ident: BFnpp2014193_CR3
  publication-title: Cereb Cortex
  doi: 10.1093/cercor/bhr332
– volume: 69
  start-page: 424
  year: 2011
  ident: BFnpp2014193_CR27
  publication-title: Biol Psychiatry
  doi: 10.1016/j.biopsych.2010.10.015
– volume: 28
  start-page: 12294
  year: 2008
  ident: BFnpp2014193_CR20
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.3116-08.2008
– volume: 36
  start-page: 133
  year: 2011
  ident: BFnpp2014193_CR13
  publication-title: Neuropsychopharmacology
  doi: 10.1038/npp.2010.96
– volume: 43
  start-page: 201
  year: 2002
  ident: BFnpp2014193_CR4
  publication-title: Synapse
  doi: 10.1002/syn.10034
– volume: 80
  start-page: 1
  year: 1966
  ident: BFnpp2014193_CR23
  publication-title: Psychol Monogr
  doi: 10.1037/h0092976
– volume: 75
  start-page: 807
  year: 2004
  ident: BFnpp2014193_CR5
  publication-title: Am J Hum Genet
  doi: 10.1086/425589
– volume: 12
  start-page: 1062
  year: 2009
  ident: BFnpp2014193_CR12
  publication-title: Nat Neurosci
  doi: 10.1038/nn.2342
– volume: 51
  start-page: 768
  year: 1995
  ident: BFnpp2014193_CR21
  publication-title: J Clin Psychol
  doi: 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1
– volume: 50
  start-page: 168
  year: 2008
  ident: BFnpp2014193_CR11
  publication-title: Dev Med Child Neurol
  doi: 10.1111/j.1469-8749.2008.02026.x
– volume: 5
  start-page: 184
  year: 2004
  ident: BFnpp2014193_CR22
  publication-title: Nat Rev Neurosci
  doi: 10.1038/nrn1343
– reference: 20631684 - Neuropsychopharmacology. 2011 Jan;36(1):133-52
– reference: 5340840 - Psychol Monogr. 1966;80(1):1-28
– reference: 21270784 - Nat Neurosci. 2011 Feb;14(2):154-62
– reference: 19291230 - Eur J Neurosci. 2009 Mar;29(5):1056-63
– reference: 9707588 - Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9991-6
– reference: 16806623 - Brain Cogn. 2006 Nov;62(2):143-76
– reference: 22764248 - J Neurosci. 2012 Jul 4;32(27):9402-9
– reference: 24498023 - PLoS One. 2014;9(1):e87109
– reference: 21531388 - Biol Psychiatry. 2011 Jun 15;69(12):e113-25
– reference: 16778890 - Nature. 2006 Jun 15;441(7095):876-9
– reference: 17063156 - Neuropsychopharmacology. 2007 May;32(5):1011-20
– reference: 14976518 - Nat Rev Neurosci. 2004 Mar;5(3):184-94
– reference: 9427330 - Neuroreport. 1997 Nov 10;8(16):3581-5
– reference: 11793426 - Synapse. 2002 Mar 1;43(3):201-7
– reference: 21168124 - Biol Psychiatry. 2011 Mar 1;69(5):424-31
– reference: 15457404 - Am J Hum Genet. 2004 Nov;75(5):807-21
– reference: 22349272 - Psychopharmacology (Berl). 2012 Aug;222(4):609-17
– reference: 18190537 - Dev Med Child Neurol. 2008 Mar;50(3):168-81
– reference: 16385186 - Alcohol Clin Exp Res. 2005 Dec;29(12):2158-69
– reference: 17574813 - Neural Netw. 2007 Aug;20(6):676-89
– reference: 22325209 - Neuron. 2012 Feb 9;73(3):595-607
– reference: 19620978 - Nat Neurosci. 2009 Aug;12(8):1062-8
– reference: 22120491 - Cereb Cortex. 2012 Nov;22(11):2575-86
– reference: 19020023 - J Neurosci. 2008 Nov 19;28(47):12294-304
– reference: 8778124 - J Clin Psychol. 1995 Nov;51(6):768-74
– reference: 25090423 - Psychol Rev. 2014 Jul;121(3):337-66
SSID ssj0015768
Score 2.3900466
Snippet Whether to continue to exploit a source of reward, or to search for a new one of potentially greater value, is a fundamental and underconstrained decision....
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 454
SubjectTerms Adult
Behavior
Benzophenones - pharmacology
Catechol O-Methyltransferase - genetics
Catechol O-Methyltransferase - metabolism
Catechol O-Methyltransferase Inhibitors - pharmacology
Dopamine
Dopamine - metabolism
Double-Blind Method
Exploitation
Exploratory Behavior - drug effects
Exploratory Behavior - physiology
Female
Genotype & phenotype
Genotyping Techniques
Humans
Hypotheses
Internal-External Control
Male
Middle Aged
Neurology
Neuropsychological Tests
Nitrophenols - pharmacology
Original
Polymorphism
Reward
Uncertainty
Young Adult
Title Dopamine, Locus of Control, and the Exploration-Exploitation Tradeoff
URI https://www.ncbi.nlm.nih.gov/pubmed/25074639
https://www.proquest.com/docview/1635037817
https://www.proquest.com/docview/1637552864
https://www.proquest.com/docview/1664208374
https://pubmed.ncbi.nlm.nih.gov/PMC4443960
Volume 40
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB4VkKpeqrL0sS1FrtRy6aYksWM7pwroIlQVhCqQ9hbFL1GpJAu7e9h_37HjDS-VWySPIyczHn_z8AzA58JRzrLcJjJ3aKBwUyaldizRpbNlrVLrlL_gfHLKjy_Yz0kxiQ63WUyrXOnEoKhNq72PfA9xQ5FSITPxfXqd-K5RProaW2iswQaqYIlyvnEwPj373ccRPJoOOLKkCVpjk5j6nlK510x9ucqMfQtB57uH0iOk-TBh8s4JdPQKXkboSPY7Xm_CM9sMYGu_QbP5akl2SUjmDF7yATw_iTHzAeyeddWplyNyfnvZajYKM_q61cstGP9AA_oK54zIr1YvZqR15LDLZB-RujEEsSLpcvYCO5PwHGt8Ezz0jG2dew0XR-Pzw-MkdllINBNynlBUvXiGS-1cVqgaLW2uROoyYaxGbOFUJk2RKV3ysjZ5zVODWoIrjfzIaMEUfQPrTdvYd0AQDVima1QJwjCX1aXTjNvc4duQFVYN4evqN1c6Ls93wvhbhVA4lRUypfJMqZApQ_jSU0-70hv_odtecayKG3BW3YrLED71w7h1fDykbmy7CDSiKHLJ2VM03CcgUIE0bzsh6BeD6FEwRHhDEPfEoyfwpbvvjzR_LkMJb8YQCPL0_dNL_wAv8COLzuOzDevzm4X9iBhornZgTUzEThT3f7unCVY
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeEHR8FAYYie2FhiWxYycPCI2tU8faakKd1LcsdmyBxJJCW6H-U_yNnJ2PbSD2trdIPieO7-z7ne_DAG8jQzkLQu3FoUEDheeJlyjDPJUYnWTS10baBOfxhA_P2OdZNNuA300ujA2rbPZEt1HnpbJn5HuIGyKfijgQH-c_PHtrlPWuNldoVGJxote_0GRbfDg-RP7uhOHRYHow9OpbBTzFRLz0KG41qLNiZUwQyQwtSy6FbwKRa4W61MggzqNAqoQnWR5m3M9xVXCp8PsBjZik-N47sMlsRmsHNj8NJqdfWr-FRe8OtybUQ-tvVofa-zTeK-a2PGbA3jsn91Ul-A-y_TtA84rGO3oID2qoSvYr2XoEG7rowtZ-gWb6xZrsEhc86k7lu3B3XPvou7B7WlXDXvfJ9DK5a9F3Pdo62estGByiwX6BffpkVKrVgpSGHFSR832SFTlBbEqqGEEnPp57rmuKE1SyuS6NeQxntzL_T6BTlIV-BgTRh2Yqwy1I5MwEWWIU4zo0-DZkhZY9eNdMc6rq4dmbN76nzvVO4xSZklqmpMiUHuy01POq1Md_6LYbjqX1gl-kl-LZgzdtMy5V63_JCl2uHI2IojDm7CYabgMeqECap5UQtINBtCoYIsoeiGvi0RLYUuHXW4pvX13JcMYQeHL_-c1Dfw33htPxKB0dT05ewH384ag6bdqGzvLnSr9E_LWUr2qhJ3B-2-vsD3saRh4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTpp4QdDxURhgJLYXGhonjp08IDTWVhvbqgptUt-y2LEFEksKbYX6r_HXcXY-toHY294i-Ww5vjvf73znM8DbyISc0UB7cWDQQeF54iXKME8lRieZ9LWR9oLz6YQfnrPPs2i2Ab-buzA2rbLZE91GnZfKnpEPEDdEfihiKgamTouYDscf5z88-4KUjbQ2z2lUInKs17_QfVt8OBoir3eDYDw6Ozj06hcGPMVEvPRC3HbQfsXKGBrJDL1MLoVvqMi1QrtqJI3ziEqV8CTLg4z7OWoIlwrnQsOIyRDHvQebAq0i68Dmp9Fk-qWNYVgk7zBsEnroCc7qtHs_jAfF3JbKpOy9C3hfN4j_oNy_kzWvWb_xQ3hQw1ayX8nZI9jQRRe29wt02S_XZI-4RFJ3Qt-FrdM6Xt-FvWlVGXvdJ2dXF70WfdejrZm93obREJ33S-zTJyelWi1IachBlUXfJ1mRE8SppMoXdKLkue-6vjhBg5vr0pjHcH4n6_8EOkVZ6GdAEIlopjLcjkTODM0SoxjXgcHRkBVa9uBds8ypqqdnX-H4nrowfBinyJTUMiVFpvRgt6WeV2U__kO303AsrZV_kV6Jag_etM2otjYWkxW6XDkaEUVBzNltNNwmP4QCaZ5WQtBOBpGrYIgueyBuiEdLYMuG32wpvn115cMZQxDK_ee3T_01bKF-pSdHk-MXcB__N6oOnnags_y50i8Rii3lq1rmCVzctZr9AVvSSko
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dopamine%2C+Locus+of+Control%2C+and+the+Exploration-Exploitation+Tradeoff&rft.jtitle=Neuropsychopharmacology+%28New+York%2C+N.Y.%29&rft.au=Kayser%2C+Andrew+S&rft.au=Mitchell%2C+Jennifer+M&rft.au=Weinstein%2C+Dawn&rft.au=Frank%2C+Michael+J&rft.date=2015-01-01&rft.pub=Nature+Publishing+Group&rft.issn=0893-133X&rft.eissn=1740-634X&rft.volume=40&rft.issue=2&rft.spage=454&rft_id=info:doi/10.1038%2Fnpp.2014.193&rft.externalDBID=HAS_PDF_LINK&rft.externalDocID=3522567981
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0893-133X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0893-133X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0893-133X&client=summon